Human Securin(PTTG1) ELISA kit

Code CSB-EL019074HU
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* The sample kit cost can be deducted from your subsequent orders of 96T full size kits of the same analyte at 1/5 per kit, until depleted in 6 months. Apply now

Product Details

Target Name
pituitary tumor-transforming 1
Alternative Names
AW555095 ELISA Kit; C87862 ELISA Kit; Cut2 ELISA Kit; EAP 1 ELISA Kit; EAP1 ELISA Kit; ESP1 associated protein 1 ELISA Kit; Esp1-associated protein ELISA Kit; hPTTG ELISA Kit; MGC126883 ELISA Kit; MGC138276 ELISA Kit; Pds1 ELISA Kit; Pituitary tumor transforming 1 ELISA Kit; Pituitary tumor transforming protein 1 ELISA Kit; Pituitary tumor-transforming 1; isoform CRA_a ELISA Kit; Pituitary tumor-transforming 1; isoform CRA_b ELISA Kit; Pituitary tumor-transforming gene 1 ELISA Kit; Pituitary tumor-transforming gene 1 protein ELISA Kit; PTTG 1 ELISA Kit; PTTG ELISA Kit; PTTG1 ELISA Kit; PTTG1 protein ELISA Kit; PTTG1_HUMAN ELISA Kit; Pttg3 ELISA Kit; Securin ELISA Kit; Tumor transforming 1 ELISA Kit; Tumor transforming protein 1 ELISA Kit; Tumor-transforming protein 1 ELISA Kit; TUTR 1 ELISA Kit; TUTR1 ELISA Kit
Abbreviation
PTTG1
Uniprot No.
Species
Homo sapiens (Human)
Sample Types
serum, plasma, tissue homogenates, cell lysates
Detection Range
31.2 pg/mL-2000 pg/mL
Sensitivity
7.8 pg/mL
Assay Time
1-5h
Sample Volume
50-100ul
Detection Wavelength
450 nm
Research Area
Cancer
Assay Principle
quantitative
Measurement
Sandwich
Precision
Intra-assay Precision (Precision within an assay): CV%<8%        
Three samples of known concentration were tested twenty times on one plate to assess.    
Inter-assay Precision (Precision between assays): CV%<10%        
Three samples of known concentration were tested in twenty assays to assess.      
               
Linearity
To assess the linearity of the assay, samples were spiked with high concentrations of human PTTG1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.  
  Sample Serum(n=4)    
1:1 Average % 92    
Range % 86-97    
1:2 Average % 107    
Range % 103-112    
1:4 Average % 88    
Range % 83-94    
1:8 Average % 86    
Range % 81-92    
Recovery
The recovery of human PTTG1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.  
 
Sample Type Average % Recovery Range    
Serum (n=5) 106 102-110    
EDTA plasma (n=4) 89 86-94    
               
               
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.  
 
pg/ml OD1 OD2 Average Corrected    
2000 2.027 2.156 2.092 1.962    
1000 1.679 1.778 1.729 1.599    
500 1.173 1.213 1.193 1.063    
250 0.715 0.722 0.719 0.589    
125 0.445 0.458 0.452 0.322    
62.5 0.305 0.319 0.312 0.182    
31.2 0.221 0.227 0.224 0.094    
0 0.129 0.131 0.130      
Troubleshooting
and FAQs
Storage
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx
Description

This Human PTTG1 ELISA Kit was designed for the quantitative measurement of Human PTTG1 protein in serum, plasma, tissue homogenates, cell lysates. It is a Sandwich ELISA kit, its detection range is 31.2 pg/mL-2000 pg/mL and the sensitivity is 7.8 pg/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
(From Uniprot)
Regulatory protein, which plays a central role in chromosome stability, in the p53/TP53 pathway, and DNA repair. Probably acts by blocking the action of key proteins. During the mitosis, it blocks Separase/ESPL1 function, preventing the proteolysis of the cohesin complex and the subsequent segregation of the chromosomes. At the onset of anaphase, it is ubiquitinated, conducting to its destruction and to the liberation of ESPL1. Its function is however not limited to a blocking activity, since it is required to activate ESPL1. Negatively regulates the transcriptional activity and related apoptosis activity of TP53. The negative regulation of TP53 may explain the strong transforming capability of the protein when it is overexpressed. May also play a role in DNA repair via its interaction with Ku, possibly by connecting DNA damage-response pathways with sister chromatid separation.
Gene References into Functions
  1. the short form of securin does not influence the expression of MYC transcriptional targets, such as TP53 and IL-8. PMID: 29989583
  2. Data strongly indicated that PTTG1 is a target gene of miR186 in osteosarcoma (OS) cells and is involved in miR186mediated suppressive effects of OS cells. PMID: 29693191
  3. Results show that PTTG1 oncoprotein overexpression may modulate cell proliferation-related regulators in myeloid leukemia. PMID: 29649138
  4. In ACTH-secreting pituitary tumors, IHC staining showed strong cytoplasmic and moderate nucleic PTTG immunoreactivity in 22 of 28 nonrecurrent tumors and in 21 of 27 recurrent tumors but no staining in the 2 normal pituitaries. PTTG was significantly increased in both the nonrecurrent and recurrent groups compared with normal pituitary glands, but there was no difference between the nonrecurrent and recurrent groups. PMID: 29432944
  5. Smurf1 interacts with and targets Securin, an inhibitor of sister-chromatid separation, for poly-ubiquitination and proteasomal degradation. PMID: 28658604
  6. PTTG-1 oexpression in meningiomas were correlated with tumor grade and proliferation rate. PMID: 29575197
  7. Results found that PTTG1 expression was significantly increased in androgen-independent prostate cancer cells and, elucidates that interleukin-6/STAT3 activation can increase PTTG1 expression and, consequently, promote the resistance to androgen deprivation therapy in castration-resistant prostate cancer by inducing EMT and increasing the cancer stem cell population. PMID: 29288516
  8. we confirmed the oncogenic function of PTTG1 in BC and demonstrated that PTTG1 is a target of miR-146a-3p. PMID: 27893422
  9. PTTG1 is an independent prognostic factor and acts as an oncogene in colorectal cancer PMID: 28219049
  10. High PTTG1 expression is associated with aggressive meningiomas. PMID: 26894859
  11. These results indicate PTTG1 may be a valuable biomarker in ovarian cancer to predict sensitivity to saracatinib, and could form the basis of a targeted prospective saracatinib trial for ovarian cancer. PMID: 27766744
  12. A relatively stable genome in retinoblastoma tumor cells is maintained by TRb1 and TRb2-mediated PTTG1 inhibition, counteracting Rb-deficiency-related genomic instability. PMID: 28242412
  13. Findings indicate that PBF and PTTG have a critical role in promoting thyroid cancer that is predictive of poorer patient outcome. PMID: 28504713
  14. PTTG-mediated FGF2 upregulation is associated with more aggressive tumor features in patients with acromegaly. Also, locally produced estrogen through aromatization might have a role in this phenomenon. PMID: 26578364
  15. All these suggest that the MAP3K M1P site is a potential interacting partner of MAP3K SH3 domain, which may mediate the intermolecular recognition between hPTTG1 and MAP3K. PMID: 27787230
  16. that PTTG1 is a novel downstream target gene of androgen receptor and take part in prostate cancer proliferation and metastasis PMID: 27756608
  17. Knockdown of PTTG1 suppresses the growth and invasion of LAC cells through upregulation of the TGFbeta1/SMAD3 signaling. PMID: 25816405
  18. PTTG1 is correlated with non-small cell lung cancer (NSCLC) progression and as an independent poor prognostic factor in NSCLC patients. PMID: 27829547
  19. Our data indicate that securin expression may serve as a strong and independent prognosticator of breast cancer outcome PMID: 26984614
  20. PTTG1 mRNA expression levels in gastric tumor tissues were significantly higher than in the corresponding adjacent normal gastric mucosa.PTTG1 mRNA and protein expression are independent prognostic factors for gastric cancer patient survival. PMID: 25627474
  21. Pttg1 may increase BC cell growth through nuclear exclusion of p27, which highlights a novel molecular regulatory machinery in tumorigenesis of BC. PMID: 26824458
  22. Data show that overexpression of c-myc proto-oncogene protein could prevent the metabolic shift induced by pituitary tumor-transforming gene (PTTG) knockwown. PMID: 26516926
  23. Report feedback loop between PTTG1 targeting miRNAs, PTTG1 and p53 that promotes pituitary tumorigenesis. PMID: 26320179
  24. knockdown of PTTG1 increased expression of integrin alpha 4 (ITGA4), ITGA5, and integrin beta 1 (ITGB1); otherwise, RhoA expression was significantly decreased PMID: 26900962
  25. Data show that pituitary tumor-transforming 1 protein (PTTG1) is over-expressed in multiple myeloma (MM) patients and is associated with poor survival. PMID: 26445238
  26. Silencing of PTTG could also inhibit tumor growth, invasion, and angiogenesis in vivo. Our data indicated that PTTG might be a potential target for glioma treatment PMID: 25908389
  27. FoxM1 binds to PTTG1 promoter to enhance PTTG1 transcription, and FoxM1-PTTG1 pathway promotes colorectal cancer migration and invasion PMID: 26264222
  28. we demonstrated here the inhibitory effect of CACP on the growth of H22 cells in vitro and in vivo, which may be through, at least partly, repression of PTTG1 and then followed by the inactivation of P13/Akt and activation of p38 MARK signaling pathways PMID: 25874498
  29. PTTG1 enhances HBV replication through suppression of P53. PMID: 26710612
  30. In peripheral area of testicular seminoma, PTTG1 staining was located in cell nucleus. In central area, staining was more intense in cytoplasm. On the other hand, in embryonal carcinoma, cells had diffuse positive staining, mainly in cytoplasm. PMID: 24754453
  31. PTTG1 is differentially expressed by benign and malignant pheochromocytoma with low sensitivity; meaning that positive immunohistochemistry result for PTTG1 is of great value to predict malignant behavior of pheochromocytoma PMID: 25871022
  32. PTTG1 is a marker for proliferative skin diseases associated with cell cycle regulation and may aid in detection of aggressive cancers PMID: 25549700
  33. Our findings provide novel molecular insights into hPTTG1-induced senescence and identify a novel mechanism by which hPTTG1 promotes metastasis by regulating the senescence-associated microenvironment. PMID: 22789011
  34. The interaction between TERT and PTTG1 by association of Ku70 might be important for the enhancement of the limited self-renewal activity of MSCs and for understanding the regulatory mechanisms of self-renewal. PMID: 24816985
  35. This study demonstrated that PTTG was expressed in most of meningioma tissues, and the degree of PTTG immunostaining was variable in the subtypes of tumors PMID: 24908230
  36. This present meta-analysis suggests that PTTG expression may be associated with tumor invasiveness and microvessel density of pituitary adenomas. PMID: 24594688
  37. The numbers of migrating cells (51.38 +/- 4.71) in the PTTG siRNA group was obviously lower. PMID: 24377512
  38. Data indicate that pituitary tumor-transforming gene 1 (PTTG1) was frequently overexpressed in oral squamous cell carcinoma (OSCC) tissues. PMID: 24879625
  39. PTTG may contribute to the malignant progression of esophageal squamous cell carcinoma (ESCC) and serve as a novel prognostic indicator for patients with ESCC. PMID: 24176776
  40. our data suggest that PTTG1 promotes the proliferation of prostate cancer cells via the inhibition of SMAD3. SMAD3 thus appears to be a novel therapeutic target for suppressing the growth of prostate cancer. PMID: 24627133
  41. high Cdc20 and securin immunoexpression identified a patient subgroup with extremely short, on average 2.4 years, breast cancer survival and triple-negative breast cancer subtype. PMID: 24853182
  42. findings suggest that PTTG1 may act as a major target of miR-655. This study improves our understanding of the mechanisms underlying ESCC pathogenesis PMID: 24314023
  43. No TTF1 or EAP1 germline mutations were associated with central pubertal disorders. TTF1 and EAP1 may affect puberty by changing expression in response to other members of puberty-associated gene networks PMID: 24051510
  44. STAT3 induces PTTG expression to facilitate tumor growth and metastasis. PMID: 23416975
  45. KLF6 directly binds and represses PTTG1 expression during induction of myeloid differentiation. PMID: 23977008
  46. The expression of hPTTG1 was correlated with differentiation levels, clinical classification and lymph node metastasis, but did not correlate with gender, age or pathological types. PMID: 23128677
  47. Overexpression of PTTG1, which encodes securin, a negative regulator of p53, was identified as a marker of poor survival in adrenocortical carcinoma. PMID: 24238056
  48. These results define hPTTG as having a central role in thyroid autocrine signaling mechanisms via growth factors, with profound implications for promotion of transformed cell growth. PMID: 23867215
  49. Enhanced expression of PTTG1 in the psoriatic epidermis may result in aberrant regulation of the cell cycle and impaired differentiation via the interplay between PTTG1 and TNF-alpha. PMID: 23677169
  50. This study identified both PTTG1 and miR-186 as potential anti-invasion targets for therapeutic intervention in non-small cell lung cancer . PMID: 23671127

Show More

Hide All

Subcellular Location
Cytoplasm. Nucleus.
Protein Families
Securin family
Tissue Specificity
Expressed at low level in most tissues, except in adult testis, where it is highly expressed. Overexpressed in many patients suffering from pituitary adenomas, primary epithelial neoplasias, and esophageal cancer.
Database Links

HGNC: 9690

OMIM: 604147

KEGG: hsa:9232

STRING: 9606.ENSP00000344936

UniGene: Hs.350966

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
webinars: DT3C facilitates antibody internalization X